← SynDRA
GSK-2636771
SynDRA canonical compound SYN0037972 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | PIK3CB |
|---|
| Mechanism of action | PI3K inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- PIK3CB INHIBITOR
- PI3-kinase p110-beta subunit inhibitor
- PI3K inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- PIK3CD
- PIK3C2B
- AAK1
- PRKCQ
- PIK3CA
- PHKG2
- PGRMC1
- PFKP
- PDXK
- PDGFRB
- PCYT1A
- PAK4
- PAICS
- OPA1
- OLA1
- NUAK2
- NTRK1
- PIK3CG
- PIM1
- PIP4K2A
- PRKACG
- PRKCD
- PRKCB
- PRKCA
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACB
- PIP4K2C
- PRKACA
- PRKAA1
- PLK4
- PKN2
- PKN1
- PKMYT1
- NQO2
- NLK
- NEK9
- MAPK15
- MAPKAPK5
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Antineoplastic Agents
- Protein Kinase Inhibitors
Cross-references
Synonyms
- GSK2636771
- GSK 2636771
- 2-methyl-1-(2-methyl-3-(trifluoromethyl)benzyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid
- UNII-DW94IAT0LS
- DW94IAT0LS
- 2-Methyl-1-((2-methyl-3-(trifluoromethyl)phenyl)methyl)-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid
- 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid
- lic acid
- XTKLTGBKIDQGQL-UHFFFAOYSA-N
- RefChem:144516
- DTXCID9082615
- PI3K-beta Inhibitor GSK2636771
- MFCD22417098
- C22H22F3N3O3
- MLS006011177
- GTPL7967
- orb1306552
- SCHEMBL1280998
- SCHEMBL29352801
- SCHEMBL29411881
- EX-A434
- GLXC-90128
- HMS3653H17
- HMS3673E13
- HMS3749O03
- BDBM50059637
- NSC768508
- NSC781258
- NSC800110
- s8002
- AKOS026750339
- CCG-269050
- CS-0747
- EBC-220134
- GSK 2636771 [WHO-DD]
- NSC-768508
- NSC-781258
- NSC-800110
Look up GSK-2636771 in the interactive SynDRA portal →